TScan Therapeutics (TCRX) Current Assets (2020 - 2025)
Historic Current Assets for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $188.2 million.
- TScan Therapeutics' Current Assets fell 3134.79% to $188.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.2 million, marking a year-over-year decrease of 3134.79%. This contributed to the annual value of $292.7 million for FY2024, which is 5070.35% up from last year.
- Per TScan Therapeutics' latest filing, its Current Assets stood at $188.2 million for Q3 2025, which was down 3134.79% from $221.1 million recorded in Q2 2025.
- TScan Therapeutics' 5-year Current Assets high stood at $299.5 million for Q2 2024, and its period low was $100.9 million during Q1 2023.
- In the last 5 years, TScan Therapeutics' Current Assets had a median value of $187.6 million in 2021 and averaged $191.8 million.
- Per our database at Business Quant, TScan Therapeutics' Current Assets skyrocketed by 35453.15% in 2021 and then plummeted by 3134.79% in 2025.
- Quarter analysis of 5 years shows TScan Therapeutics' Current Assets stood at $165.7 million in 2021, then decreased by 25.07% to $124.1 million in 2022, then skyrocketed by 56.48% to $194.2 million in 2023, then surged by 50.7% to $292.7 million in 2024, then crashed by 35.72% to $188.2 million in 2025.
- Its Current Assets was $188.2 million in Q3 2025, compared to $221.1 million in Q2 2025 and $254.8 million in Q1 2025.